SCHEMBL6499068

SCHEMBL6499068

O=C(NC1Cc2ccccc2C1)c1ccccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 7/20 0.66
▸ SMYD3 Q9H7B4 1/20 0.58
▸ KMT2A Q03164 4/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ GAA P10253 2/20 0.57
▸ CRBN Q96SW2 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ NAMPT P43490 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ PSMD14 O00487 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490792 0.86 GRM5 (0.54) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL2241357 0.85 GRM5 (0.77) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL6501250 0.82 KDM4E (0.53) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL2246381 0.82 GRM5 (0.82) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL7986175 0.82 GRM5 (0.72) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL16394406 0.82 GRM5 (0.88) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL2590689 0.81 GRM5 (0.80) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL22449377 0.81 GRM5 (0.80) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL9965813 0.81 GRM5 (0.66) GRM5SMYD3KMT2AKDM4EGAA
SCHEMBL31116604 0.81 GRM5 (0.70) GRM5SMYD3KMT2AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 — — US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 — — EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 GRM5 3334/4885SMYD3 2731/4885KMT2A 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback